<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-1981556-B1" country="EP" doc-number="1981556" kind="B1" date="20140101" family-id="38327619" file-reference-id="311113" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146553506" ucid="EP-1981556-B1"><document-id><country>EP</country><doc-number>1981556</doc-number><kind>B1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-07701032-A" is-representative="NO"><document-id mxw-id="PAPP154827429" load-source="docdb" format="epo"><country>EP</country><doc-number>07701032</doc-number><kind>A</kind><date>20070119</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140447104" ucid="KR-20060010712-A" load-source="docdb"><document-id format="epo"><country>KR</country><doc-number>20060010712</doc-number><kind>A</kind><date>20060203</date></document-id></priority-claim><priority-claim mxw-id="PPC140449695" ucid="KR-2007000335-W" load-source="docdb"><document-id format="epo"><country>KR</country><doc-number>2007000335</doc-number><kind>W</kind><date>20070119</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130708</date></intention-to-grant-date><search-report-dispatch-date><date>20120713</date></search-report-dispatch-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988121999" load-source="ipcr">A61L  27/54        20060101AFI20130618BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1988095835" load-source="docdb" scheme="CPC">A61L  27/34        20130101 LI20131030BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988107519" load-source="docdb" scheme="CPC">A61L2430/02        20130101 LA20131030BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988119050" load-source="docdb" scheme="CPC">A61L  27/54        20130101 LI20130531BHEP        </classification-cpc><classification-cpc mxw-id="PCL1988134808" load-source="docdb" scheme="CPC">A61L  27/10        20130101 FI20131030BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132193002" lang="DE" load-source="patent-office">KNOCHENTRANSPLANTAT UND MIT TYP-I-KOLLAGENBINDEPEPTIDEN IMMOBILISIERTE GERÜSTMATERIALIEN</invention-title><invention-title mxw-id="PT132193003" lang="EN" load-source="patent-office">BONE GRAFT AND SCAFFOLDING MATERIALS IMMOBILIZED WITH TYPE I COLLAGEN BINDING PEPTIDES</invention-title><invention-title mxw-id="PT132193004" lang="FR" load-source="patent-office">MATIÈRES DE GREFFON OSSEUX ET D'ÉCHAFAUDAGE IMMOBILISÉES À L'AIDE DE PEPTIDES DE LIAISON AU COLLAGÈNE DE TYPE 1</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR918149929" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SEOUL NAT UNIV IND FOUNDATION</last-name><address><country>KR</country></address></addressbook></applicant><applicant mxw-id="PPAR918146532" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918135163" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>PARK YOON-JEONG</last-name><address><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR918140245" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>PARK, YOON-JEONG</last-name></addressbook></inventor><inventor mxw-id="PPAR918997043" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>PARK, YOON-JEONG</last-name><address><street>110-402, Lotte Apt. Guro 5-dong, Guro-gu</street><city>Seoul 152-770</city><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR918134338" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>CHUNG CHONG-PYOUNG</last-name><address><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR918140133" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>CHUNG, CHONG-PYOUNG</last-name></addressbook></inventor><inventor mxw-id="PPAR918997044" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>CHUNG, CHONG-PYOUNG</last-name><address><street>2701, Jamsil Daewoo Lake World Apt. 58-1, Songpa-dong, Songpa-gu</street><city>Seoul 138-170</city><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR918149394" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>LEE SEUNG-JIN</last-name><address><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR918170209" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>LEE, SEUNG-JIN</last-name></addressbook></inventor><inventor mxw-id="PPAR918997042" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>LEE, SEUNG-JIN</last-name><address><street>10-1106, Gwangjang Apt. Yeouido-dong, Yeongdeungpo-gu</street><city>Seoul 150-762</city><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR918137810" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>LEE JUE-YEON</last-name><address><country>KR</country></address></addressbook></inventor><inventor mxw-id="PPAR918146369" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>LEE, JUE-YEON</last-name></addressbook></inventor><inventor mxw-id="PPAR918997045" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>LEE, JUE-YEON</last-name><address><street>914-304, Jugong Apt. Burim-dong, Gwacheon-si</street><city>Gyeonggi-do 427-736</city><country>KR</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR918997047" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION</last-name><iid>100748180</iid><address><street>56-1 San, Sinrim-9-dong</street><city>Gwanak-gu Seoul 151-050</city><country>KR</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR918997046" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Adam, Holger</last-name><suffix>et al</suffix><iid>100048040</iid><address><street>Kraus &amp; Weisert Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15</street><city>80539 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="KR-2007000335-W"><document-id><country>KR</country><doc-number>2007000335</doc-number><kind>W</kind><date>20070119</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2007089084-A1"><document-id><country>WO</country><doc-number>2007089084</doc-number><kind>A1</kind><date>20070809</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548978368" load-source="docdb">AT</country><country mxw-id="DS548987555" load-source="docdb">BE</country><country mxw-id="DS548828948" load-source="docdb">BG</country><country mxw-id="DS548975698" load-source="docdb">CH</country><country mxw-id="DS548883897" load-source="docdb">CY</country><country mxw-id="DS548978369" load-source="docdb">CZ</country><country mxw-id="DS548987556" load-source="docdb">DE</country><country mxw-id="DS548883898" load-source="docdb">DK</country><country mxw-id="DS548883899" load-source="docdb">EE</country><country mxw-id="DS548977653" load-source="docdb">ES</country><country mxw-id="DS548828949" load-source="docdb">FI</country><country mxw-id="DS548828950" load-source="docdb">FR</country><country mxw-id="DS548987557" load-source="docdb">GB</country><country mxw-id="DS548883900" load-source="docdb">GR</country><country mxw-id="DS548978370" load-source="docdb">HU</country><country mxw-id="DS548975699" load-source="docdb">IE</country><country mxw-id="DS548883901" load-source="docdb">IS</country><country mxw-id="DS548828951" load-source="docdb">IT</country><country mxw-id="DS548883902" load-source="docdb">LI</country><country mxw-id="DS548973109" load-source="docdb">LT</country><country mxw-id="DS548978371" load-source="docdb">LU</country><country mxw-id="DS548973114" load-source="docdb">LV</country><country mxw-id="DS548973115" load-source="docdb">MC</country><country mxw-id="DS548987558" load-source="docdb">NL</country><country mxw-id="DS548973116" load-source="docdb">PL</country><country mxw-id="DS548975700" load-source="docdb">PT</country><country mxw-id="DS548987559" load-source="docdb">RO</country><country mxw-id="DS548973117" load-source="docdb">SE</country><country mxw-id="DS548975701" load-source="docdb">SI</country><country mxw-id="DS548828952" load-source="docdb">SK</country><country mxw-id="DS548883903" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63957241" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b>TECHNICAL FIELD</b></heading><p id="p0001" num="0001">The present invention relates to a bone graft material and a scaffold for tissue engineering applications, which have bone calcification-promoting peptides immobilized on the surface thereof and a pharmaceutical composition comprising a peptide inducing type I collagen binding, and more particularly, to a bone graft material and a scaffold for tissue engineering applications (hereinafter, referred to as scaffold), which have peptides specifically binding to type I collagen immobilized on the surface thereof, and a pharmaceutical composition for promoting tissue regeneration containing type I collagen binding-inducing peptide.</p><heading id="h0002"><b>BACKGROUND ART</b></heading><p id="p0002" num="0002">Periodontal tissue that supports teeth consists generally of the alveolar bone, the periodontal ligament tissue forming the periodontal membrane between the alveolar bone and the teeth, and the connective tissue. The loss of alveolar bone caused by the progression of periodontitis involves the loss of periodontal ligament tissue, and at sites of the loss of periodontal ligament tissue, the normal repair of alveolar bone and periodontal ligament tissue after the treatment of periodontitis becomes impossible due to excessive growth of connective tissue. Also, even when new bone is formed, the periodontal ligament tissue will not be normally differentiated so that the loss of tooth function can be caused.<!-- EPO <DP n="2"> --></p><p id="p0003" num="0003">To solve such problems, an attempt to induce the complete regeneration or new formation of tissue using an artificial barrier membrane together with autografting in guided periodontal regeneration is actively made. Also, for the regeneration of bone tissue, a tissue engineering scaffold is used as a bone graft material. Since cases showing the effective induction of periodontal tissue and bone tissue by the introduction of bone graft materials and scaffolds (<nplcit id="ncit0001" npl-type="s"><text>Camelo, M. et al., International J. Periodont. Restorative Dent. 21:109, 2001</text></nplcit>) were reported for recent ten years, various materials, including bone powder particles made of bovine bone, have been used as bone materials and tissue engineering scaffolds for tissue regeneration.</p><p id="p0004" num="0004">Meanwhile, in order to improve the efficiency of such bone graft materials and scaffolds for tissue regeneration, studies to attach materials capable of improving tissue regeneration to the bone graft materials and the scaffolds are now conducted. Firstly, protein ingredients of extracellular matrices are adhered to the surface of bone graft materials and scaffolds, then calcification is performed to finally form bone tissues. Herein, if collagen, main ingredients of extracellular matrices is induced, early reaction of bone tissue regeneration is rapidly induced to result in increasing the regeneration rate. Furthermore, such extracellular matrices is reported to be excellent in the ability of the repair and regeneration of damaged tissue, and their excellent ability to regenerate tissue was also shown in the results of actual clinical tests.</p><p id="p0005" num="0005">Such examples include artificial biocompatible material comprising a porous sintered body of calcium phosphate and collagen derivatives as mucosal adjuvants (Korean Patent Registration <patcit id="pcit0001" dnum="KR105511"><text>105511</text></patcit>) an artificial bone material for replacing natural bone which promotes osteoblast adhesion (<patcit id="pcit0002" dnum="KRP487693"><text>KRP 487693</text></patcit>), collagen scaffold for bone regeneration (Korean Patent Registration <patcit id="pcit0003" dnum="KR1427557"><text>1427557</text></patcit>), etc.<!-- EPO <DP n="3"> --></p><p id="p0006" num="0006">However, collagen, the most materials consisting of extracellular matrix is high-molecular-weight proteins having several tens of kDa, and it is extracted directly from biological tissues or prepared as a recombinant protein; and thus being relatively expensive and thermally unstable, therefore it is difficult to prepare various pharmaceutical compositions.</p><p id="p0007" num="0007"><patcit id="pcit0004" dnum="WO2005089826A1"><text>WO 2005/089826 A1</text></patcit> discloses bone graft material or scaffold having an osteogenesis-promoting peptide immobilized on the surface, which include several bone sialoprotein (BSP) derived sequences.</p><p id="p0008" num="0008"><patcit id="pcit0005" dnum="WO0004941A1"><text>WO 00/04941 A1</text></patcit> discloses bone scaffolds comprising a surface attached bioactive molecule such as collagen binding, RGD-based, peptides.</p><p id="p0009" num="0009">Accordingly, the present inventors have made extensive efforts to solve the above-described problems occurring in the prior art, and consequently found that the rate of bone tissue regeneration is increased by fixing the peptides capable of inducing rapid adhesion of collagen (main ingredient of extracellular matrix) on the surface of bone graft materials and scaffolds, furthermore, the risk of immune reaction is low in its application to the body because of small molecular weights thereof, and the effect of drugs lasts because of its stable existence in the body as well. On the basis of these findings, the present invention has been completed.</p><heading id="h0003"><b>SUMMARY OF THE INVENTION</b></heading><p id="p0010" num="0010">An object of the present invention is to provide with a bone graft material for promoting bone tissue regeneration and a scaffold for tissue engineering applications, which have a peptide inducing type I collagen binding immobilized on the surface thereof.<!-- EPO <DP n="4"> --><!-- EPO <DP n="5"> --></p><p id="p0011" num="0011">In the present invention, a peptide inducing type I collagen binding comprises any one amino acid sequence among SEQ ID NO: 1 to SEQ ID NO: 6, and more preferably, the peptide has an addition of cysteine at N-terminal end of amino acid sequence selected from SEQ ID NO: 1 to SEQ ID NO: 6.</p><p id="p0012" num="0012">Another features and embodiments of the present invention will be more clarified from the following "detailed description" and the appended "claims".<!-- EPO <DP n="6"> --></p><heading id="h0004"><b>BRIEF DESCRIPTION OF DRAWINGS</b></heading><p id="p0013" num="0013"><ul><li><figref idrefs="f0001">FIG. 1</figref> shows the analysis of adhesion degree between collagen and the peptides according to the present invention.</li><li><figref idrefs="f0002">FIG. 2</figref> shows confocal laser scanning microscopic images showing the cell adhesion patterns of the inventive peptides. In <figref idrefs="f0002">FIG. 2</figref>, (a) shows the adhesion pattern of cells to the surface non-covered with peptides, and (b) (c) and (d) show the adhesion patterns of cells on bone graft surfaces with immobilized peptides derived from bone sialoprotein 1(BSP 1) of <i>Oryctolagus cuniculus,</i> respectively.</li><li><figref idrefs="f0003">FIG. 3</figref> is confocal laser scanning microscopic images showing an adhesion degree of calcium stained with calcein after culturing the inventive peptides in a medium for forming a hard tissue for given periods, which added with broth of the inventive peptides. In <figref idrefs="f0003">FIG. 3</figref>, (a) is non-treatment group with peptides, and (b) (c) and (d) show aspects of cell calcification on bone graft surfaces immobilized with peptides derived from bone sialoprotein 1(BSP 1) of <i>Oryctolagus cuniculus,</i> respectively.</li><li><figref idrefs="f0004">FIG. 4</figref> is photographs showing the results of Western blot for the amount of intracellular signal transfer marker ERK in cells collected after exposing the inventive peptides to the cultured cells for given times (NT: cells non-treated with peptides; C1: cells treated with peptides of SEQ ID NO: 1; C2: cells treated with peptides of SEQ ID NO: 2; C3: cells treated with peptides of SEQ ID NO: 3).</li></ul><!-- EPO <DP n="7"> --></p><heading id="h0005"><b>DETAILED DESCRIPTION OF THE INVENTION, AND PPRFERRED EMBODIMENTS</b></heading><p id="p0014" num="0014">In one aspect, the present invention relates to a bone graft material for promoting bone tissue regeneration and a scaffold for tissue engineering applications, which have a peptide inducing type I collagen binding immobilized on the surface thereof. In other words, the present invention relates to a bone graft material and a scaffold for tissue regeneration, on the surfaces of which a peptide inducing collagen binding is immobilized so that the bone graft material and the scaffold have pharmacological activity, whereby their efficiency in the regeneration of bone tissue or other tissues can be improved.</p><p id="p0015" num="0015">The peptide inducing type I collagen binding comprises any one amino acid sequence among SEQ ID NO: 1 to SEQ ID NO: 6. In the present invention, a peptide essentially comprising a specific amino acid sequence includes peptides having a similar function, in which another amino acid sequence is added to the amino acid sequence of the present invention. Furthermore, the peptide includes peptides having an addition of cysteine at the N-terminal end of the amino acid sequence, as well as peptides having an addition of other amino group. For example, there is a peptide in which cysteine is linked at the N-terminal end of amino acid sequence selected from SEQ ID NO: 1 to SEQ ID NO: 6, via a spacer consisting of two glycines (CGG- and CGGGGG-) in order to facilitate to immobilize to a bone graft material or a scaffold chemically.</p><p id="p0016" num="0016">In the present invention, all kinds and types of bone graft materials and polymer scaffolds can be used if they are used in the technical field. Preferred examples of these bone graft materials include organism-derived bone mineral powders and porous blocks originated from autogeneous bone such as bovine bone and porcine bone etc., synthetic hydroxyapatite powder and porous blocks thereof, tricalcium phosphate powders and porous blocks thereof, monocalcium phosphate powder<!-- EPO <DP n="8"> --> and porous blocks, bone graft materials containing silicon dioxide (silica) as a main ingredient, bone-packing graft materials containing a mixture of silica and polymer as a main ingredient, chitosan, fine particles containing biocompatible polymers as a main ingredient, and titanium and the like.</p><p id="p0017" num="0017">Moreover, examples of polymer scaffolds include chitosan, porous scaffolds containing biocompatible polymers as a main ingredient and three-dimensional porous scaffolds of titanium. Herein, the surface of bone graft materials and scaffolds is preferably modified to facilitate binding of active peptides.</p><p id="p0018" num="0018">The peptide inducing collagen binding according to the present invention promotes binding of collagen which is a main ingredient of extracellular matrix in primary differentiation of osteoblast, whereby promoting a calcification, the last step of differentiation. Thus, the peptide inducing collagen binding has suitable characteristics for the regeneration of bone tissue and periodontal tissue.</p><p id="p0019" num="0019">The peptide inducing collagen binding according to the present invention has free amino group or cysteine at the N-terminal end and thus easy to immobilize on the surface of bone graft materials and scaffolds by crosslinkers. Crosslinkers suitable for use in the present invention include, but are not limited to, 1,4-bis-maleimidobutane (BMB), 1,11-bis-maleimido tetraethyleneglycol (BM[PEO]<sub>4</sub>), 1-ethyl-3-[3-dimethyl aminopropyl] carbodiimide hydrochloride (EDC), succinimidyl-4-[N-maleimido methylcyclohexane-1-carboxy-[6-amidocaproate]] (SMCC) and sulfo-SMCC, succimidyl 6-[3-(2-pyridyldithio)-ropionamido] hexanoate] (SPDP) and sulfo-SPDP, m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) and sulfo-MBS, succimidyl [4-(p-maleimidophenyl) butyrate] (SMPB) and sulfo-SMPB.</p><p id="p0020" num="0020">In another aspect, the present invention relates to a pharmaceutical composition for promoting tissue regeneration, wherein a peptide inducing collagen binding is<!-- EPO <DP n="9"> --> embedded in the pharmaceutical composition for promoting tissue regeneration to have pharmacological activity, whereby their efficiency in the regeneration of bone tissue or other tissues can be improved.</p><p id="p0021" num="0021">In the present pharmaceutical composition for promoting tissue regeneration, all kinds and types of pharmaceutical formulation can be used if they are used in the technical field, specifically, ointment type or cream type that can be applied to skin is preferred. For the ointment or cream, general carriers such as fat, fatty oil, lanolin, vaseline, paraffin, lead, resin, plastic, glycols, higher alcohol, glycerin, water, emulsifier, suspension agent or proper additives can be utilized.</p><p id="p0022" num="0022">Additionally, the pharmaceutical composition may be used in the form of a gel, and general carriers such as chitosan, alginate, prophylene glycol, prophylene glycol alginate, poloxamer, chondroitin sulfate and the like can preferably be used as the gel</p><p id="p0023" num="0023">Hereinafter, the present invention will be described in further detail about a bone graft material and a scaffold for tissue engineering applications, which have the invention a peptide inducing type I collagen binding immobilized thereon, and a pharmaceutical composition containing a peptide inducing type I collagen binding according to the present invention</p><p id="p0024" num="0024">The peptide inducing collagen binding used in the present invention is obtained by isolating and extracting active site amino acid sequence from protein constituting the extracellular matrix and then subjected to chemical modification so as to maintain its active structure.</p><p id="p0025" num="0025">Specifically, the peptide inducing collagen binding essentially contains any one amino acid sequence among amino acid sequences at position 85-105 of bone sialoprotein 1(BSP 1) of <i>Oryctolagus cuniculus:</i> YRLKRSKS (SEQ ID NO: 1),<!-- EPO <DP n="10"> --> KMFHVSNAQYPGA (SEQ ID NO: 2), YRLKRSKSKMFHVSNAQYPGA (SEQ ID NO: 3); and amino acid sequences at position 149-169 of bone sialoprotein I of human: YGLRSKS (SEQ ID NO: 4), KKFRRPDIQYPDAT (SEQ ID NO: 5), YGLRSKSKKFRRPDIQYPDAT (SEQ ID NO: 6).</p><p id="p0026" num="0026">In the process of chemical modification for stabilizing peptide structure, a cysteine is added to the N-terminal end of amino acid sequence selected from the amino acid sequences in the form of CGG or CGGGGG spacer, and synthesized chemically to prepare a peptide.</p><p id="p0027" num="0027">The modification process of the surface of a bone graft material and a polymer scaffold is performed in order to bind the peptide prepared above to the surface therof. Herein, the used bone graft material and polymer scaffold is any one selected from the group consisting of organism-derived bone mineral powders and porous blocks originated from autogeneous bone, bovine bone and porcine bone, synthetic hydroxyapatite powders and porous blocks thereof, tricalcium phosphate powders and porous blocks thereof, monocalcium phosphate powders and porous blocks thereof, bone graft materials containing silicon dioxide (silica) as a main ingredient, bone-packing graft materials containing a mixture of silica and polymer as a main ingredient, chitosan, fine particles containing biocompatible polymers as main ingredient and porous scaffolds thereof, titanium and three-dimensional scaffolds thereof etc., and the modification process may be little different depending on its kinds.</p><p id="p0028" num="0028">The modification process of surface is performed by removing the impurities on the surface of a bone graft material and a polymer scaffold, and then adding a crosslinker to bind the peptides to the surface chemically. Herein, a functional group capable of binding with cysteine located at the end of peptide, for example, a -SH group is introduced in the surface or the surface is treated to form an amine (NH2), thereby achieving efficient cross-linking by cosslinker.<!-- EPO <DP n="11"> --></p><p id="p0029" num="0029">Particles of a bone graft material or a scaffold bonded with crosslinker are allowed to react with the peptide prepared above, and then washed to obtain the bone graft material and the scaffold having the peptides immobilized. The peptides are chemically bound to the surface of bone graft materials and scaffolds so that they are immobilized on the surface in an amount of preferably 0.1-10 mg/cm<sup>2</sup>. More preferably, the peptides consist of 5∼30 amino acids and are immobilized on the surface in an amount of 1-5 mg/cm<sup>2</sup>.</p><p id="p0030" num="0030">In addition, the peptides are sealed to prepare a pharmaceutical composition for promoting tissue regeneration, wherein the composition is prepared in a form of a liquid, a gel, ointment, or cream. Especially, the ointment or cream is prepared by evenly mixing the peptide with carriers such as fat, fatty oil, lanolin, vaseline, paraffin, lead, resin, plastic, glycols, higher alcohol, glycerin, water, emulsifier, suspension agent and proper additives, which are generally used in preparing ointment or cream in the art.</p><heading id="h0006"><b>Examples</b></heading><p id="p0031" num="0031">Hereinafter, the present invention will be described in further detail by examples. It will however be obvious to a person skilled in the art that these examples are provided for illustrative purpose only and are not construed to limit the scope of the present invention.</p><p id="p0032" num="0032">Especially, the following examples illustrate only peptides inducing collagen binding of SEQ ID NO: 1 to 3, but it will be obvious to a person skilled in the art that the similar effect could be obtained when peptides inducing collagen binding of amino acid sequences at position 149-169 of bone sialoprotein I of human: YGLRSKS (SEQ ID NO: 4), KKFRRPDIQYPDAT (SEQ ID NO: 5), YGLRSKSKKFRRPDIQYPDAT (SEQ ID NO: 6) are synthesized and cysteine<!-- EPO <DP n="12"> --> and the like is added to the end thereof.</p><heading id="h0007"><u><b>Example 1:</b> Synthesis of peptide containing the type I collagen-binding active domain</u></heading><p id="p0033" num="0033">Cysteine was linked at each N-terminal end of peptides having amino acid sequences of SEQ ID NO: 1. 2 and 3 comprising a type I collagen-binding active domain of Bone sialoprotein 1(BSP 1) of <i>Oryctolagus cuniculus</i> via a spacer (GGG-, and CGGGGG), thus synthesizing a peptide inducing type I collagen binding.</p><p id="p0034" num="0034">The synthesized peptide's affinity to type I collagen was examined using Biacore X (Biacore Co., Sweden). After the type I collagen was bound to CM5 chip, the amount of peptides binding with collagen was quantitated while flowing the prepared peptide dissolved to be 4µmol into micro-channels of Biacore X (<figref idrefs="f0001">FIG. 1</figref>). As a result, as shown in <figref idrefs="f0004">FIG. 4</figref>, the peptide of SEQ ID NO: 3 showed the highest affinity to collagen, and the peptide of SEQ ID NO: 2 showed the lowest affinity to collagen.</p><heading id="h0008"><u><b>Example 2:</b> Immobilization of peptide inducing type I collagen binding on bovine bone-derived bone mineral particles</u></heading><p id="p0035" num="0035">Bovine bone-derived bone mineral particles were washed with ethanol under reduced pressure and then left to stand in a vacuum oven at 100 °C for 20 hours so as to remove impurities from the surface. The surface of the bone mineral particles was treated with a solution of 3-aminopropyl ethoxysilane (APTES) dissolved in hexane, followed by washing. This resulted in the formation of amine residues on the surface, to which crosslinker BMB was then added and bound. Bone mineral particles bonded with crosslinker were allowed to react with each peptide synthesized in example 1 for 12 hours, followed by washing, thus<!-- EPO <DP n="13"> --> yielding the bone mineral particles having the peptides immobilized on the surface thereof.</p><heading id="h0009"><u><b>Example 3:</b> Immobilization of peptide inducing type I collagen binding on synthetic hydroxyapatite and tricalcium phosphate</u></heading><p id="p0036" num="0036">Bone graft powders of synthetic hydroxyapatite and tricalcium phosphate were washed with ethanol under reduced pressure and then left to stand in a vacuum oven at 100 °C for 20 hours so as to remove impurities from the surface. The surface of the bone mineral particles was treated with a solution of 3-aminopropyl ethoxysilane (APTES) in hexane, followed by washing. This resulted in the formation of amine residues on the surface, to which crosslinker BMB was then added and bound. The bone mineral particles with the bound crosslinker were allowed to react with each peptide synthesized in example 1 for 12 hours, followed by washing, thus yielding the bone mineral particles having the peptides immobilized on the surface thereof.</p><heading id="h0010"><u><b>Example 4:</b> Immobilization of peptide inducing type I collagen binding on bone graft material with chitosan</u></heading><p id="p0037" num="0037">A bone graft material with chitosan prepared in the form of a powdery or porous scaffold was added to 2 ml of phosphate buffer (pH 7.4) to hydrate the surface. To this solution, sulfo-SMCC as a crosslinker was added at a concentration of 5 mg/ml, and the mixture was stirred for 2 hours to introduce functional groups on the surface of the bone graft material with chitosan. After 2 hours of reaction at ambient temperature, the bone graft material with chitosan was washed and allowed to react with each solution of 10 mg of each peptide synthesized in example 1, dissolved in each 100 µl of phosphate buffer for 24 hours, followed by washing, thus yielding the bone graft material with chitosan having the peptide immobilized thereon.<!-- EPO <DP n="14"> --></p><heading id="h0011"><u><b>Example 5:</b> Immobilization of peptide inducing type I collagen binding on bone graft material with polylactic acid</u></heading><p id="p0038" num="0038">A bone grafting powder or porous scaffold of polylactic, acid was added to phosphate buffer (pH 4.7) to hydrate the surface, followed by reaction with 20 mg/ml of cystamine hydrochloride solution. To this solution, EDC was added dropwise to activate the carboxylic acid on the surface of the bone graft material. The mixture was reacted for 24 hours, washed, and allowed to react with 1 ml of dithiothreniol (DTT) solution (30 mg/ml) for 24 hours so as to introduce sulfhydryl groups onto the surface of the polylactic acid. The modified polylactic acid bone graft material was mixed with each peptide synthesized in example 1 so as to immobilize by S-S bonds between the sulfhydryl groups of the bone grafting material and the peptides.</p><heading id="h0012"><u><b>Example 6:</b> Test of cell adhesion of peptides according to the present invention</u></heading><p id="p0039" num="0039">Human-osteocarcoma cells (KCLB No.21543) were inoculated on the surface of bone graft materials prepared in Examples 2 and then cultured for 2 hours. The bone graft materials with the cultured human-osteocarcoma cell were fixed with 2% glutaraldehyde solution. The fixed bone graft materials were treated with 1% triton X-100 and then added with a fluorescent-labeled phalloidin solution, thus staining the attached cytoplasm. Then, after the samples were washed and fixed, the cells adhered to the bone graft materials were observed with a confocal laser scanning microscope (<figref idrefs="f0002">FIG. 2</figref>).</p><p id="p0040" num="0040">In <figref idrefs="f0002">FIG. 2</figref>, (a) shows the cell adhesion on the surface coated with BSA(Bovine serum albumin), and (b), (c) and (d) show the cell adhesions on the surfaces coated with peptides in which cysteine was added at each N-terminal end of amino acid sequences of SEQ ID NO: 1, 2 and 3, respectively. As a result, for<!-- EPO <DP n="15"> --> the surface coated with BSA, spherical and unstable adhesion aspect of the cells was observed, whereas on the surfaces coated with the peptides inducing collagen binding, the stable adhesion of the cells (including the elongation of the cytoplasm in most of the cells after 3 hours of the cell culture) was observed.</p><heading id="h0013"><u><b>Example 7:</b> Test of calcification by peptides according to the present invention</u></heading><p id="p0041" num="0041">The bone graft materials prepared in Examples 2 was added to a medium for forming a hard tissue containing calcein (fluorescent marker of calcium), and human mesenchymally derived stem cells (C<sub>2</sub>Cl<sub>2</sub>: ATCC CRL-1772) were cultured for 14 days. The cultured osteoblasts werefixed with 2% glutaraldehyde solution and treated with 1% triton X-100 and then added with a fluorescent-labeled phalloidin solution, thus staining the fixed cytoplasm. Then, after the samples were washed and fixed, the calcium adhered to extracellular matrix was observed with a confocal laser scanning microscope (<figref idrefs="f0003">FIG. 3</figref>), on the surface of the bone graft materials.</p><p id="p0042" num="0042">In <figref idrefs="f0003">FIG. 3</figref>, (a) shows the group without peptides of the present invention, and (b), (c) and (d) show the calcium adhesions within cells by peptides in which cysteine was added at each N-terminal end of amino acid sequences of SEQ ID NO: 1, 2 and 3, respectively. As a result, the groups with peptide inducing collagen binding, showed much more fluorescence than (a) group without the peptides, so it could be confirmed that the peptides inducing collagen binding promote a calcification of cells.</p><heading id="h0014"><u><b>Example 8:</b> Expression of differentiation marker proteins in osteoblasts cultured on surface of peptide-immobilized bone graft material according to the present invention</u></heading><p id="p0043" num="0043">In order to examine the expression of differentiation marker protein in osteoblasts cultured on the surface of the bone graft material on which peptides added with<!-- EPO <DP n="16"> --> cysteine at each N-terminal end of amino acid sequences of SEQ ID NOs: 1, 2 and 3, prepared in example 2 according to the present invention were immobilized, the peptides were exposed to human mesenchymally derived stem cells (C2C12) for 30 min, and collected to measure the amount of ERK protein, a marker proteins involved in intracellular signal transfer, by Western blot.</p><p id="p0044" num="0044">The human mesenchymally derived stem cells were transplanted to 60mm of petridish, treated with peptides for 30 min. Whole intracellular protein was extracted and quantitated by Bradford method. 40µg of protein was electrophoresed on acrylamide gel and transferred to nitrocellulose membrane, and ERK, intracellular signal transmission protein within cell was reacted with the antibody of phosphorylated ERK (pERK), followed by reacting with the second antibody labeled with a marker. The membrane was developed to observe the protein bands and measure densities thereof (<figref idrefs="f0004">FIG. 4</figref>).</p><p id="p0045" num="0045">As a result, as shown in <figref idrefs="f0004">FIG. 4</figref>, the expression of the phosphorylated ERK (pERK) in the cells treated with the peptides (C1, C2, C3) was significantly increased as compared to the case of the cells non-treated with the peptides (NT). This suggests that the differentiation into bone tissue of the cells grown on the surface of the bone graft material immobilizing the peptides inducing collagen binding was promoted.<!-- EPO <DP n="17"> --></p><heading id="h0015"><b>INDUSTRIAL APPLICABILITY</b></heading><p id="p0046" num="0046">As described and proved above in detail, the present invention provides the bone graft material and scaffold for tissue engineering applications having a surface immobilized with collagen binding-inducing peptide, capable of have suitable effect of tissue regeneration with small and low-concentrated dose. In the inventive bone graft material and scaffold for tissue engineering applications, the cells related to regeneration by collagen binding-inducing peptide adhered to the surface, promote an adhesion of type I collagen binding-inducing peptide (main ingredients of extracellular matrix) to increase differentiation rate into bone tissues, and promote a calcification which is last step of bone regeneration to maximize a tissue regeneration finally. Additionally, the risk of immune reaction is low in application to the body because of small molecular weights thereof, and the effect of drugs is lasted because of existing stably in the body as well, thus having an excellent convenience in case of regeneration operations of periodontal tissues, alveolar bones and other bone tissues.<!-- EPO <DP n="18"> --></p><heading id="h0016">SEQUENCE LISTING</heading><p id="p0047" num="0047"><ul><li>&lt;110&gt; seoul National University Industry Foundation</li><li>&lt;120&gt; Bone Graft and scaffolding Materials Immoblized with Type I Collagen Binding Peptides</li><li>&lt;130&gt; 19205EP</li><li>&lt;140&gt; <patcit id="pcit0006" dnum="KR07701032"><text>07 701 032.0</text></patcit><br/>
&lt;141&gt; 2007-01-19</li><li>&lt;150&gt; <patcit id="pcit0007" dnum="KR1020060010712"><text>KR 10-2006-0010712</text></patcit><br/>
&lt;151&gt; 2006-02-03</li><li>&lt;160&gt; 7</li><li>&lt;170&gt; PatentIn version 3.2</li><li>&lt;210&gt; 1<br/>
&lt;211&gt; 8<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Oryctolagus cuniculus</li><li>&lt;400&gt; 1
<img id="ib0001" file="imgb0001.tif" wi="68" he="7" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 2<br/>
&lt;211&gt; 13<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Oryctolagus cuniculus</li><li>&lt;400&gt; 2
<img id="ib0002" file="imgb0002.tif" wi="110" he="8" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 3<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Oryctolagus cuniculus</li><li>&lt;400&gt; 3
<img id="ib0003" file="imgb0003.tif" wi="135" he="21" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 4<br/>
&lt;211&gt; 7<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Homo sapiens</li><li>&lt;400&gt; 4
<img id="ib0004" file="imgb0004.tif" wi="59" he="8" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 5<br/>
&lt;211&gt; 14<br/>
&lt;212&gt; PRT<br/>
<!-- EPO <DP n="19"> -->&lt;213&gt; Homo sapiens</li><li>&lt;400&gt; 5
<img id="ib0005" file="imgb0005.tif" wi="118" he="8" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 6<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Homo sapiens</li><li>&lt;400&gt; 6
<img id="ib0006" file="imgb0006.tif" wi="135" he="22" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 7<br/>
&lt;211&gt; 6<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial Sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; spacer</li><li>&lt;400&gt; 7
<img id="ib0007" file="imgb0007.tif" wi="51" he="8" img-content="dna" img-format="tif"/></li></ul></p></description><claims mxw-id="PCLM56979212" lang="DE" load-source="patent-office"><!-- EPO <DP n="23"> --><claim id="c-de-01-0001" num="0001"><claim-text>Knochentransplantatmaterial, das ein Peptid, welches Typ-I-Kollagen-Bindung induziert, immobilisiert an einer Oberfläche des Knochentransplantatmaterials, umfasst, wobei das Peptid eine Aminosäuresequenz, ausgewählt aus der Gruppe, bestehend aus SEQ ID NO: 1 bis SEQ ID NO: 6, umfasst.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Knochentransplantatmaterial gemäß Anspruch 1, wobei das Peptid, das Typ-I-Kollagen-Bindung induziert, eine Addition von Cystein am N-terminalen Ende der Aminosäuresequenz, ausgewählt aus SEQ ID NO: 1 bis SEQ ID NO: 6, hat.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Knochentransplantatmaterial gemäß Anspruch 2, wobei das Cystein als CGGG- oder CGGGGG-Spacertyp addiert ist.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Knochentransplantatmaterial gemäß den Ansprüchen 1 bis 3, wobei das Knochentransplantatmaterial ein beliebiges ist, das aus der Gruppe, bestehend aus von einem Organismus stammenden Knochenmaterialpulvern und porösen Blöcken, die aus autogenem Knochen, Rinderknochen und Schweineknochen stammen, synthetischen Hydroxyapatitpulvern und porösen Blöcken, Tricalciumphosphatpulvern und porösen Blöcken, Monocalciumphosphatpulvern und porösen Blöcken, Knochentransplantatmaterialien, die Siliciumdioxid (Silica) als Hauptbestandteil enthalten, Knochenpackungspropfmaterialien, die ein Gemisch aus Siliciumdioxid und Polymer als Hauptbestandteil enthalten, Chitosan, feinen Partikeln, die biokompatible Polymere als Hauptbestandteile enthalten und Titan, ausgewählt ist.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Knochentransplantatmaterial gemäß Anspruch 1, wobei das Peptid, das Typ-I-Kollagen-Bindung induziert, durch ein Vernetzungsmittel immobilisiert ist.<!-- EPO <DP n="24"> --></claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Knochentransplantatmaterial gemäß Anspruch 5, wobei das Vernetzungsmittel eins oder mehrere, ausgewählt aus der Gruppe, bestehend aus 1,4-Bis-malimidobutan (BMB), 1,11-Bis-maleimido-tetraethylenglycol (BM[PEO]<sub>4</sub>), 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimid-Hydrochlorid (EDC), Succinimidyl-4[N-maleimidomethylcyclohexan-1-carboxy-[6-amidocaproat]] (SMCC) und Sulfo-SMCC, Succimidyl-6-[3-(2-pyridyldithio)-ropianamido]hexanoat (SPDP) und Sulfo-SPDP), m-Maleimidobenzoyl-N-hydroxysuccinimidester (MBS) und Sulfo-MBS, Succimidyl-[4-(p-maleimidophenyl)butyrat] (SMPB) und Sulfo-SMPB, ist.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Gerüst für Tissue-Engineering-Anwendungen, das ein Peptid, das Typ-I-Kollagen-Bindung induziert, immobilisiert an einer Oberfläche des Gerüstes umfasst, wobei das Peptid eine Aminosäuresequenz, ausgewählt aus der Gruppe, bestehend aus SEQ ID NO: 1 bis SEQ ID NO: 6, umfasst.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Gerüst für Tissue-Engineering-Anwendungen gemäß Anspruch 1, wobei das Peptid, das Typ-I-Kollagen induziert, eine Addition von Cystein am N-terminalen Ende der Aminosäureseqzenz, ausgewählt aus SEQ ID NO: 1 bis SEQ ID NO: 6, hat.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Gerüst für Tissue-Engineering-Anwendung gemäß Anspruch 8, wobei das Cystein als CGG oder CGGGGG-Spacertyp angefügt ist.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Gerüst für Tissue-Engineering-Anwendungen gemäß den Ansprüchen 7-9, wobei das Gerüst für Tissue-Engineering-Anwendungen eins oder mehrere, ausgewählt aus der Gruppe, bestehend aus Chitosan, porösen Gerüsten, die biokompatible Polymere als Hauptbestandteil enthalten, und dreidimensionalen Gerüsten aus Titan, ist.<!-- EPO <DP n="25"> --></claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Gerüst für Tissue-Engineering-Anwendungen gemäß Anspruch 7, wobei das Peptid, das Typ-I-Kollagen-Bindung induziert, durch ein Vernetzungsmittel immobilisiert ist.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Gerüst für Tissue-Engineering-Anwendungen gemäß Anspruch 11, wobei das Vernetzungsmittel eins oder mehrere, ausgewählt aus der Gruppe, bestehend aus 1,4-Bis-malimidobutan (BMB), 1,11-Bis-maleimido.tetraethylenglycol (BM[PEO]<sub>4</sub>), 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimid-hydrochlorid (EDC), Succinimidyl-4[N-maleimidomethylcyclohexan-1-carboxy-[6-amidocaproat]] (SMCC) und Sulfo-SMCC, Succimidyl-6-[3-(2-pyridyldithio)-ropianamido]hexanoat] (SPDP) und Sulfo-SPDP), m-Maleimidobenzoyl-N-hydroxysuccinimidester (MBS) und Sulfo-MBS, Succimidyl-[4-(p-maleimidophenyl)butyrat] (SMB) und Sulfo-SMPB, ist.</claim-text></claim></claims><claims mxw-id="PCLM56979213" lang="EN" load-source="patent-office"><!-- EPO <DP n="20"> --><claim id="c-en-01-0001" num="0001"><claim-text>A bone graft material comprising a peptide inducing type I collagen binding immobilized on a surface of the bone graft material, wherein the peptide comprises any one amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 6.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The bone graft material according to claim 1, wherein the peptide inducing type I collagen binding has an addition of cysteine at N-terminal end of amino acid sequence selected from SEQ ID NO: 1 to SEQ ID NO: 6.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The bone graft material according to claim 2, wherein said cysteine is added as CGG or CGGGGG spacer type.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The bone graft material according to claims 1 to 3, wherein the bone graft material is any one selected from the group consisting of organism-derived bone mineral powders and porous blocks originated from autogeneous bone, bovine bone and porcine bone, synthetic hydroxyapatite powders and porous blocks, tricalcium phosphate powders and porous blocks, monocalcium phosphate powders and porous blocks, bone graft materials containing silicon dioxide (silica) as main ingredient, bone-packing graft materials containing a mixture of silica and polymer as main ingredient, chitosan, fine particles containing biocompatible polymers as main ingredient, and titanium.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The bone graft material according to claim 1, wherein the peptide inducing type I collagen binding is immobilized by a crosslinker.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The bone graft material according to claim 5, wherein the crosslinker is any one or more selected from the group consisting of 1,4-bis-maleimidobutane (BMB), 1,11-bis-maleimido tetraethyleneglycol (BM[PEO]<sub>4</sub>), 1-ethyl-3-[3-dimethyl aminopropyl]<!-- EPO <DP n="21"> --> carbodiimide hydrochloride (EDC), succinimidyl-4-[N-maleimido methylcyclohexane-1-carboxy-[6-amidocaproate]] (SMCC) and sulfo-SMCC, succimidyl 6-[3-(2-pyridyldithio)-ropionamido] hexanoate] (SPDP) and sulfo-SPDP), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) and sulfo-MBS, succimidyl [4-(p-maleimidophenyl) butyrate] (SMPB) and sulfo-SMPB.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A scaffold for tissue engineering applications comprising a peptide inducing type I collagen binding immobilized on a surface of the scaffold, wherein the peptide comprises any one amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 6.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The scaffold for tissue engineering applications according to claim 1, wherein the peptide inducing type I collagen has an addition of cysteine at N-terminal end of the amino acid sequence selected from SEQ ID NO: 1 to SEQ ID NO: 6.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The scaffold for tissue engineering applications according to claim 8, wherein said cysteine is added as CGG or CGGGGG spacer type.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The scaffold for tissue engineering applications according to claims 7 to 9, wherein the scaffold for tissue engineering applications is any one or more selected from the group consisting of chitosan, porous scaffolds containing biocompatible polymers as main ingredient and three-dimensional scaffolds of titanium.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The scaffold for tissue engineering applications according to claim 7, wherein the peptide inducing type I collagen binding is immobilized by a crosslinker.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The scaffold for tissue engineering applications according to claim 11, wherein the crosslinker is any one or more selected from the group consisting of 1,4-bis-maleimidobutane (BMB), 1,11-bis-maleimido tetraethyleneglycol (BM[PEO]<sub>4</sub>), 1-ethyl-3-[3-dimethyl aminopropyl] carbodiimide hydrochloride (EDC), succinimidyl-4-[N-maleimido<!-- EPO <DP n="22"> --> methylcyclohexane-1-carboxy-[6-amidocaproate]] (SMCC) and sulfo-SMCC, succimidyl 6-[3-(2-pyridyldithio)-ropionamido] hexanoate] (SPDP) and sulfo-SPDP), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) and sulfo-MBS, succimidyl [4-(p-maleimidophenyl) butyrate] (SMPB) and sulfo-SMPB.</claim-text></claim></claims><claims mxw-id="PCLM56979214" lang="FR" load-source="patent-office"><!-- EPO <DP n="26"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Matière de greffon osseux comprenant un peptide induisant la liaison du collagène de type I immobilisé sur une surface de la matière de greffon osseux, dans laquelle le peptide comprend l'une quelconque des séquences d'acides aminés choisies dans le groupe constitué de SEQ ID NO : 1 à SEQ ID NO : 6.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Matière de greffon osseux selon la revendication 1, dans laquelle le peptide induisant la liaison du collagène de type I présente une addition de cystéine à l'extrémité N-terminale d'une séquence d'acides aminés choisie parmi SEQ ID NO : 1 à SEQ ID NO : 6.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Matière de greffon osseux selon la revendication 2, dans laquelle ladite cystéine est ajoutée sous la forme d'un espaceur de type CGG ou CGGGGG.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Matière de greffon osseux selon les revendications 1 à 3, dans laquelle la matière de greffon osseux est l'une quelconque choisie dans le groupe constitué des poudres minérales osseuses dérivées d'organismes et des blocs poreux provenant<!-- EPO <DP n="27"> --> d'un os autogène, d'un os de bovin et d'un os de porcin, des poudres et des blocs poreux d'hydroxyapatite synthétique, des poudres et des blocs poreux de phosphate de tricalcium, des poudres et des blocs poreux de phosphate de monocalcium, des matières de greffon osseux contenant du dioxyde de silicium (silice) en tant qu'ingrédient principal, des matières de greffon à garniture osseuse contenant un mélange de silice et de polymère en tant qu'ingrédient principal, du chitosan, des fines particules contenant des polymères biocompatibles en tant qu'ingrédient principal, et du titane.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Matière de greffon osseux selon la revendication 1, dans laquelle le peptide induisant la liaison du collagène de type I est immobilisé par un agent de réticulation.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Matière de greffon osseux selon la revendication 5, dans laquelle l'agent de réticulation est un ou plusieurs agents de réticulation choisis dans le groupe constitué du 1,4-bis-maléimidobutane (BMB), du 1,11-bis-maléimidotétraéthylèneglycol (BM[PEO]<sub>4</sub>), du chlorhydrate de 1-éthyl-3-[3-diméthyl aminopropyl]-carbodiimide (EDC), du 4-[N-maléimidométhylcyclohexane-1-carboxy[6-amidocaproate]] de succinimidyle (SMCC) et du sulfo-SMCC, du 6-[3-(2-pyridyldithio)-ropionamido] hexanoate] de succimidyle (SPDP) et du sulfo-SPDP, d'un ester de m-maléimidobenzoyl-N-hydroxysuccinimide (MBS) et du sulfo-MBS, du [4-(p-maléimidophényl)butyrate] de succimidyle (SMPB) et du sulfo-SMPB.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Structure de soutien pour des applications d'ingénierie tissulaire comprenant un peptide induisant<!-- EPO <DP n="28"> --> la liaison du collagène de type I immobilisé sur une surface de la structure de soutien, dans laquelle le peptide comprend l'une quelconque des séquences d'acides aminés choisies dans le groupe constitué de SEQ ID NO : 1 à SEQ ID NO : 6.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Structure de soutien pour des applications d'ingénierie tissulaire selon la revendication 1, dans laquelle le peptide induisant la liaison du collagène de type I présente une addition de cystéine à l'extrémité N-terminale d'une séquence d'acides aminés choisie parmi SEQ ID NO : 1 à SEQ ID NO : 6.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Structure de soutien pour des applications d'ingénierie tissulaire selon la revendication 8, dans laquelle la cystéine est ajoutée sous la forme d'un espaceur de type CGG ou CGGGGG.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Structure de soutien pour des applications d'ingénierie tissulaire selon les revendications 7 à 9, dans laquelle la structure de soutien pour des applications d'ingénierie tissulaire est une ou plusieurs choisies dans le groupe constitué du chitosan, des structures poreuses de soutien contenant des polymères biocompatibles en tant qu'ingrédient principal et des structures tridimensionnelles de soutien à base de titane.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Structure de soutien pour des applications d'ingénierie tissulaire selon la revendication 7, dans laquelle le peptide induisant la liaison du collagène de type I est immobilisé par un agent de réticulation.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Structure de soutien pour des applications d'ingénierie tissulaire selon la revendication 11, dans laquelle l'agent de réticulation est un ou plusieurs<!-- EPO <DP n="29"> --> agents de réticulation choisis dans le groupe constitué du 1,4-bis-maléimidobutane (BMB), du 1,11-bis-maléimidotétraéthylèneglycol (BM[PEO]<sub>4</sub>), du chlorhydrate de 1-éthyl-3-[3-diméthyl aminopropyl]-carbodiimide (EDC), du 4-[N-maléimidométhylcyclohexane-1-carboxy[6-amidocaproate]] de succinimidyle (SMCC) et du sulfo-SMCC, du 6-[3-(2-pyridyldithio)-ropionamido] hexanoate] de succimidyle (SPDP) et du sulfo-SPDP, d'un ester de m-maléimidobenzoyl-N-hydroxysuccinimide (MBS) et du sulfo-MBS, du [4-(p-maléimidophényl)butyrate] de succimidyle (SMPB) et du sulfo-SMPB.</claim-text></claim></claims><drawings mxw-id="PDW16668801" load-source="patent-office"><!-- EPO <DP n="30"> --><figure id="f0001" num="1"><img id="if0001" file="imgf0001.tif" wi="133" he="112" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="31"> --><figure id="f0002" num="2(a),2(b),2(c),2(d)"><img id="if0002" file="imgf0002.tif" wi="165" he="174" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="32"> --><figure id="f0003" num="3(a),3(b),3(c),3(d)"><img id="if0003" file="imgf0003.tif" wi="159" he="175" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="33"> --><figure id="f0004" num="4"><img id="if0004" file="imgf0004.tif" wi="140" he="81" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
